Pixel RF

The PixelRF is highly effective on all skin types (Fitzpatrick I-IV) and treatments can be administered year rough with no seasonal restrictions. Unlike dermal rollers or low power bipolar RF applicators that superficially ablate and heat the skin, the PixelRF causes evaporation, mechanical damage and thermal damage deep beneath the epidermis-dermis surfacing. This provides significant dermal impact with minimal epidermal disruption.

The Future of Fractionated Skin Resurfacing is here

The Accent Family platforms now features the Pixel®RF. Using Micro Plasma Technology and In-Motion™ refractive radiofrequency, the PixelRFallows you to both ablate and heat skin through a controlled, focused delivery of energy. Healthy skin around the treated area helps to accelerate the healing process thus improving result and reducing patient down. The result is fresh, smooth and radiant skin. Best of all, the PixelRFrequires no consumables.

Here's what industry leaders have to say about the

PixelRF:

"Another dimension in the fight against aging. PixelRF technology has given us another dimension in the fight against aging. Since fractionated resurfacing with RF technology does not harm the skin's outer layer, the healing time is faster than traditional CO2 lasers. As we noticed during our study The Micro Plasma Technology? creates multiple, controlled microperforations within small zones of thermal injury, similar to the pattern created by many fractionated skin resurfacing lasers. During the procedure, just a small portion of the tissue is ablated. The remaining tissue supplies the healing that leads to the elimination of irregular epidermal pigmentation, tightening of dermal collagen and the smoothing that results from the stimulation of the skin's deeper layers. The fact that patients are experiencing less discomfort and a shorter down-time has made this technology a hit in my practice."
Dr. Michael Gold, M.D.
Gold Skin Care Center - Nashville, TN

"Skin resurfacing of the face is quick and well tolerated with topical numbing. Initial results have been more impressive than we had been achieving."
Jeffrey A. Hunt, D.O.